# RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years

> **NCT03626701** · NA · TERMINATED · sponsor: **Avita Medical** · enrollment: 19 (actual)

## Conditions studied

- Burns

## Interventions

- **DEVICE:** RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device
- **COMBINATION_PRODUCT:** Mepilex® Ag Wound Dressing
- **PROCEDURE:** Conventional autografting (only when indicated)

## Key facts

- **NCT ID:** NCT03626701
- **Lead sponsor:** Avita Medical
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-03
- **Primary completion:** 2021-06-23
- **Final completion:** 2022-06-03
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** In June 2021, the US FDA approved expanded use of the RECELL System for treatment of acute full-thickness thermal burns in patients 1-month of age and older (removing the prior limitation of use in patients younger than 18 years of age).
- **Last updated:** 2024-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03626701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03626701, "RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03626701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*